Tag: featured

July 24, 2024

The study results offer hope for patients who wish to avoid the burden of frequent Factor VIII injections. But some questions about the treatment remain. As with other gene therapies that hold out the promise of one-time solution for a […]

July 24, 2024

Republican-controlled states have passed various laws regulating medication abortion in the past, said Daniel Grossman, an OB-GYN and a reproductive health researcher at the University of California-San Francisco. But after the Dobbs v. Jackson Women’s Health Organization decision in 2022, […]

July 23, 2024

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal body weight,” with his cholesterol below 200 for the first time in 20 years. “I feel fantastic,” […]

July 22, 2024

Agilent Technologies has signed a definitive agreement to acquire BIOVECTRA, a contract development and manufacturing organization (CDMO) based in Canada, for a sum of $925 million. The acquisition agreement was announced in a July 22, 2024 press release. While the […]

July 22, 2024

At the start of 2024, optimism had returned to biotech. Investor cash flowed back toward drug companies and initial public offerings, a useful barometer of the sector’s health, picked up in a sign of the market’s strengthening. But IPOs have […]

July 17, 2024

Since NGM’s founding in 2007, the company’s research has covered a range of therapeutic areas. Its progress led to an initial public offering in 2019, which was initially followed by a run-up in the company’s stock price. But clinical setbacks […]

July 16, 2024

The new funds will be used for mid-stage clinical trials of ASN51, an oral small-molecule inhibitor of O-GlcNAcase (OGA), which has emerged in recent years as a possible target for the treatment of tauopathies, including Alzheimer’s. Studies have shown that […]

July 16, 2024

Affecting approximately one in every 40,000 people, FA is a neurodegenerative movement disorder and the most common form of inherited ataxia. The typical age of disease onset is between ten and 15 years, with initial symptoms including unsteady posture, frequent […]

July 15, 2024

Revolution Medicines is one of a handful of biotechnology and pharmaceutical firms looking to exploit drug research advances that have made RAS mutations easier to target. Mutations in the gene are frequently a trigger for cancers of the lungs, pancreas […]

July 15, 2024

Friedreich’s ataxia is known as a neurodegenerative disorder, as the progressive nerve damage it causes affects a person’s coordination and ability to walk or speak. But the most common reason people die from the condition is a type of cardiomyopathy […]

July 10, 2024

Flagship’s robust funding round highlights a general recovery in biotech investment. A number of venture capital firms brought in fresh cash this year, including Foresite Capital, Sands Capital, Scion Life Sciences and a life sciences arm of Goldman Sachs. Arch […]

July 10, 2024

The Dutch biotech said a higher dose of the gene therapy slowed progression by 80% compared to a matched control group, measured using the Unified Huntington’s Disease Rating Scale (cUHDRS), 24 months after it was dosed, in a pair of […]

July 8, 2024

Genezen, a gene therapy contract development and manufacturing organization (CDMO), and uniQure, a gene therapy company, announced on July 1, 2024 that they have entered into an agreement under which Genezen will acquire uniQure’s commercial gene therapy operations in Lexington, […]

July 8, 2024

Lilly is launching a tender offer to acquire all outstanding shares of Morphic for a purchase price of $57 per share in cash, prompting shares in the biotech to rocket 77% from $31.84 to $56.40 at the time of writing. […]

July 3, 2024

The US regulator has cleared donanemab as Kisunla for use in patients with mild cognitive impairment or the mild dementia stage of Alzheimer’s with confirmed amyloid plaques, becoming the third drug in the class after Eisai/Biogen’s short-lived Aduhelm (aducanumab) and current rival Leqembi (lecanemab). The Alzheimer’s […]

July 3, 2024

The Series B – led by Forbion and joined by other investors, including Syncona, Oxford Science Enterprises, and Oxford University Innovation – takes the total raised by Beacon since its formation last year to $290 million, making it a rising […]

July 2, 2024

For patients with gout who cannot get relief using standard therapies, daily life can be a painful, debilitating experience. The disease is a painful form of inflammatory arthritis caused by elevated levels of uric acid in the blood resulting in […]

July 1, 2024

Like many of its cell therapy peers, Artiva reshuffled its strategy hoping to ride a recent wave of investor interest in autoimmune disease research. The company is one of a number of biotechs to emerge in recent years to develop […]

July 1, 2024

The Lexington plant is a central production hub for UniQure, which describes it as “one of the world’s leading, most versatile, gene therapy manufacturing facilities.” The company has for years pitched it as a competitive advantage in the field, affording […]

June 27, 2024

On June 24, 2024, FDA posted a conversation on its website with Yoni Tyberg, associate director of the Special Program Staff in the Office of New Drugs, regarding the progress of the modernization of the New Drug Regulatory Program (NDRP). […]